Hepatobiliary Cancer Coverage from Every Angle

Laura A. Dawson, MD, on Sorafenib vs Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma

Posted: Tuesday, January 31, 2023

Laura A. Dawson, MD, of Canada’s Princess Margaret Cancer Centre, discusses the clinical implications of her phase III findings, which may define a new standard treatment option for patients with advanced hepatocellular carcinoma, especially in the presence of macrovascular invasion. The NRG/RTOG1112 study showed that stereotactic body radiation therapy administered prior to sorafenib vs sorafenib alone, improved overall survival, progression-free survival, and time to disease progression.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.